Jointown Pharmaceutical Group Co., Ltd. Class A

Jointown Pharmaceutical Group Co., Ltd. Class A

SSSE:600998
5.27
CNY
+0.02
(+0.38%)
0.41EPS
13.11P/E
25.46BMarket Cap
Apr 27Next Earn

Total Valuation

CNY

As of September 30, 2026, Jointown Pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 25.46B, placing it among publicly traded companies globally. Its enterprise value stands at 31.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap25.46B
Enterprise Value31.14B

Important Dates

Jointown Pharmaceutical Group Co., Ltd. Class A's next confirmed earnings release is scheduled for April 27, 2027.

Earnings Date4/27/2027

Share Statistics

As of September 30, 2026, Jointown Pharmaceutical Group Co., Ltd. Class A has 5.04B shares outstanding.

Shares Outstanding5.04B

Valuation Ratios

As of September 30, 2026, Jointown Pharmaceutical Group Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 13.11. The price-to-sales ratio is 0.15, and the price-to-book ratio stands at 0.93.

PE Ratio13.11
PS Ratio0.15
PB Ratio0.93
P/TBV Ratio1.08

Enterprise Valuation

As of September 30, 2026, Jointown Pharmaceutical Group Co., Ltd. Class A trades at an EV/EBITDA multiple of 10.68 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.68 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 31.14B versus a market cap of 25.46B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.18
EV / EBITDA10.68
EV / EBIT10.68

Financial Position

As of September 30, 2026, Jointown Pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 45.19, indicating elevated leverage, while an interest coverage ratio of 2.61 demonstrates limited ability to service its debt obligations.

Current Ratio1.25
Quick Ratio0.28
Debt / Equity45.19
Debt / EBITDA5.99
Interest Coverage2.61

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 5.74M in revenue per employee across its workforce of 29,862.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee5.74M
Employee Count29,862.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Jointown Pharmaceutical Group Co., Ltd. Class A recorded 795.51M in income tax expense. That works out to an effective tax rate of 27.54, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.89B, leaving 1.96B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax795.51M
Effective Tax Rate27.54

Stock Price Statistics

CNY

As of the close on November 17, 2026, Jointown Pharmaceutical Group Co., Ltd. Class A's stock has gained approximately 2.93% over the past 52 weeks. The 50-day moving average sits at 5.07, while the 200-day moving average is 5.09.

52-Week Price Change2.93%
50-Day Moving Average5.07
200-Day Moving Average5.09

Income Statement

CNY

Over the twelve months ended September 30, 2026, Jointown Pharmaceutical Group Co., Ltd. Class A generated 171.51B in revenue and converted that into 1.96B in net income, yielding earnings per share of 0.41. EBITDA reached 2.92B, while operating income came in at 4.35B.

Revenue171.51B
Gross Profit13.73B
Operating Income4.35B
Pretax Income2.89B
Net Income1.96B
EBITDA2.92B
EBIT2.92B
Earnings Per Share (EPS)0.41

Balance Sheet

CNY

As of September 30, 2026, Jointown Pharmaceutical Group Co., Ltd. Class A holds 22.93B in cash and equivalents against 17.46B in total debt, resulting in a net debt position of -6.08B. Total book value stands at 27.49B, with working capital of 20.61B providing operational flexibility.

Cash & Cash Equivalents22.93B
Total Debt17.46B
Net Debt-6.08B
Equity (Book Value)27.49B
Book Value Per Share5.45
Working Capital20.61B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-1.26B

Margins

Over the twelve months ended September 30, 2026, Jointown Pharmaceutical Group Co., Ltd. Class A posted a gross margin of 8.00, reflecting its pricing power and cost economics. The operating margin of 2.54 and net profit margin of 1.14 provide insight into operational efficiency.

Gross Margin8.00
Operating Margin2.54
Pretax Margin1.68
Profit Margin1.14
EBITDA Margin1.70

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Jointown Pharmaceutical Group Co., Ltd. Class A paid dividends of 0.28 per share. The dividend payout ratio of 65.02 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -7.33, meaning Jointown Pharmaceutical Group Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.28
Payout Ratio65.02
Shareholder Yield-7.33

Stock Splits

Jointown Pharmaceutical Group Co., Ltd. Class A's most recent stock split took place on June 7, 2024 with a 100:129 split ratio.

Last Split Date6/7/2024
Split Ratio100:129

Scores

As of September 30, 2026, Jointown Pharmaceutical Group Co., Ltd. Class A has an Altman Z-Score of 2.11, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.11